ENPP2 and pemphigus foliaceus: The ATX inhibitor from Galapagos Pharmaceuticals, GLPG1690 exhibited a good PK/PD profile in experimental animal model of PF and has entered Phase III clinical trials after completing the Phase II studies in IPF patients.